Hematologic Neoplasms clinical trials at UC Irvine
3 in progress, 2 open to eligible people
open to eligible people ages 18 years and up
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
Orange, California and other locations
open to eligible people ages 18-70
This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.
Sorry, accepting new patients by invitation only
This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients with hematologic malignancies. Its purpose of is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies.
Irvine, California and other locations
Our lead scientists for Hematologic Neoplasms research studies include Stefan Octavian Ciurea.